A Prospective, Multicentre, Non-Interventional Study Evaluating the Bleeding Incidence in Patients with Von Willebrand Disease Undergoing On-Demand Treatment (WIL-29)

Study identification

• EU PAS number:
  EUPAS29946
• Study ID:
  42926
• Official title and acronym:
  A Prospective, Multicentre, Non-Interventional Study Evaluating the Bleeding Incidence in Patients with Von Willebrand Disease Undergoing On-Demand Treatment (WIL-29)
• DARWIN EU® study:
  No
• Study countries:
  Belarus

  Bulgaria

  Hungary

  Moldova, Republic of

  Russian Federation

  Ukraine

  United States
• Study description:
  The primary objective of this study is to characterise the bleeding and treatment pattern of patients with type 3, type 2 (except 2N), or severe type 1 von Willebrand disease receiving routine on-demand treatment with a von Willebrand factor-containing product.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 20 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:28/02/2019

Actual:18/02/2019

Study start date

Planned:18/07/2019

Actual:18/07/2019

Data analysis start date

Planned:30/06/2020

Date of final study report

Planned:01/12/2021

Actual:27/08/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Octapharma AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable